This Article Full Text Full Text (PDF) All Versions of this Article: 108/3/270    most recent 01.CIR.0000079163.97653.CDv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Brien, K. D. Articles by Albers, J. J. Search for Related Content PubMed PubMed Citation Articles by O’Brien, K. D. Articles by Albers, J. J. Related Collections Lipids Chronic ischemic heart disease

(Circulation. 2003;108:270.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Cell-Associated and Extracellular Phospholipid Transfer Protein in Human Coronary Atherosclerosis

Kevin D. O’Brien, MD; Simona Vuletic, MD; Thomas O. McDonald, MS; Gertrud Wolfbauer, PhD; Katherine Lewis, PhD; An-Yue Tu, PhD; Santica Marcovina, PhD; Thomas N. Wight, PhD; Alan Chait, MD; John J. Albers, PhD

From the Divisions of Cardiology (K.D.O., T.O.M.) and Metabolism, Endocrinology and Nutrition (S.V., G.W., K.L., A.-Y.T., S.M., A.C., J.J.A.), Department of Medicine, University of Washington, and Hope Heart Institute (T.N.W.), Seattle, Wash.

Correspondence to John J. Albers, PhD, Northwest Lipid Research Laboratories, 2121 N 35th St, Seattle, WA 98103. E-mail jja{at}u.washington.edu

Background— Phospholipid transfer protein (PLTP) plays an important role in HDL particle metabolism and may modulate hepatic secretion of apolipoprotein B–containing lipoproteins. However, whether PLTP might participate directly in human atherosclerotic lesion formation is unknown.

Methods and Results— The cellular and extracellular distributions of PLTP were determined in normal and atherosclerotic human coronary lesions with a monoclonal antibody to human PLTP. Cell types (smooth muscle cells [SMCs] or macrophages), apolipoproteins (apoA-I, apoB, and apoE), and extracellular matrix proteoglycans (biglycan and versican) were identified on adjacent sections with monospecific antibodies. Minimal extracellular PLTP was detected in nonatherosclerotic coronary arteries, but extracellular and cellular PLTP immunostaining was widespread in atherosclerotic lesions. PLTP was detected in foam cell SMCs and in foam cell macrophages, which suggests that cellular cholesterol accumulation might increase PLTP expression in both cell types. This was confirmed by in vitro studies demonstrating that cholesterol loading of macrophages leads to 2- to 3-fold increases in PLTP steady-state mRNA levels, protein expression, and activity. PLTP also was detected in an extracellular distribution, colocalizing with apoA-I, apoB, apoE, and the vascular proteoglycan biglycan. In gel mobility shift assays, both active and inactive recombinant PLTP markedly increased HDL binding to biglycan, which suggests that PLTP may mediate lipoprotein binding to proteoglycans independent of its phospholipid transfer activity.

Conclusions— PLTP is present in human atherosclerotic lesions, and its distribution suggests roles for PLTP in both cellular cholesterol metabolism and lipoprotein retention on extracellular matrix.

Key Words: lipoproteins • apolipoproteins • atherosclerosis • lipids • cells

This article has been cited by other articles:

				H. Samyn, M. Moerland, T. van Gent, R. van Haperen, J. Metso, F. Grosveld, M. Jauhiainen, A. van Tol, and R. de Crom Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study J. Lipid Res., December 1, 2008; 49(12): 2504 - 2512. [Abstract] [Full Text] [PDF]

				N. J. Hime, A. S. Black, J. J. Bulgrien, and L. K. Curtiss Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP J. Lipid Res., October 1, 2008; 49(10): 2113 - 2123. [Abstract] [Full Text] [PDF]

				J. F. Oram, G. Wolfbauer, C. Tang, W. S. Davidson, and J. J. Albers An Amphipathic Helical Region of the N-terminal Barrel of Phospholipid Transfer Protein Is Critical for ABCA1-dependent Cholesterol Efflux J. Biol. Chem., April 25, 2008; 283(17): 11541 - 11549. [Abstract] [Full Text] [PDF]

				N. Ogier, A. Klein, V. Deckert, A. Athias, G. Bessede, N. Le Guern, L. Lagrost, and C. Desrumaux Cholesterol Accumulation Is Increased in Macrophages of Phospholipid Transfer Protein-Deficient Mice: Normalization by Dietary Alpha-Tocopherol Supplementation Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2407 - 2412. [Abstract] [Full Text] [PDF]

				R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 190 - 196. [Abstract] [Full Text] [PDF]

				M. Lee-Rueckert, R. Vikstedt, J. Metso, C. Ehnholm, P. T. Kovanen, and M. Jauhiainen Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells J. Lipid Res., August 1, 2006; 47(8): 1725 - 1732. [Abstract] [Full Text] [PDF]

				J. F. Oram and J. W. Heinecke ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease Physiol Rev, October 1, 2005; 85(4): 1343 - 1372. [Abstract] [Full Text] [PDF]

				K. D. O'Brien, T. O. McDonald, V. Kunjathoor, K. Eng, E. A. Knopp, K. Lewis, R. Lopez, E. A. Kirk, A. Chait, T. N. Wight, et al. Serum Amyloid A and Lipoprotein Retention in Murine Models of Atherosclerosis Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 785 - 790. [Abstract] [Full Text] [PDF]

				J. F. Oram, G. Wolfbauer, A. M. Vaughan, C. Tang, and J. J. Albers Phospholipid Transfer Protein Interacts with and Stabilizes ATP-binding Cassette Transporter A1 and Enhances Cholesterol Efflux from Cells J. Biol. Chem., December 26, 2003; 278(52): 52379 - 52385. [Abstract] [Full Text] [PDF]